Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
CytoDyn Inc CYDY
(Total Views: 417)
Posted On: 05/26/2021 9:36:47 PM
Post# of 154975
Posted By: MD VIROLOGIST
Re: chazzledazzle #91925
You nailed it, the endpoint of treatment in this case is not a milligram dose or a serum value. Half life does not filter in, if RO drops and the drug is still present, I would try to increase serum levels till RO increases. This becomes the CLINICAL treatment, not the lap top treatment. Give flexibility to the clinician within a trial design and amazing results could be forthcoming. The endpoint is efficacy which can be measured simply by RO regardless of weight, gender lean body mass. And I am not peddling INCelldx kits, have whomever in Brazil do the study!!

Study design becomes touchy with adding a placebo blood draw and changing doses based on lab measurements, but can be done. I know if I were treating critical COVID in the ICU I would treat to max RO, and even go beyond the dose if needed since toxicity is not an issue.













(5)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site